Search
Ipratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol
Amphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalAmphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. … After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935.
Potassium alum
go.drugbank.com/drugs/DB09087ApprovedWithdrawnPotassium alum is considered by the FDA as a generally recognized as safe (GRAS) substance. … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]
Disulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalIt is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.
XL765
go.drugbank.com/drugs/DB05241InvestigationalIt is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigationalDasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. … [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Idoxuridine
go.drugbank.com/drugs/DB00249ApprovedWithdrawnAn analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
Enflurane
go.drugbank.com/drugs/DB00228ApprovedVet approvedWithdrawnEnflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.
Turoctocog alfa
go.drugbank.com/drugs/DB09109Approved[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalAs such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].